Sessioni Comunicazioni Orali
PHARMACOECONOMICS, PHARMACOEPIDEMIOLOGY & PHARMACOVIGILANCE I
25/10/2017 / 14.30 - 16.30
| 94 | WEB-BASED REPORTING OF ADVERSE DRUG REACTIONS IN ITALY 1)Arzenton E. 2)Sottosanti L. 3)Opri S. 4)Magro L. 5)Viola E. 6)Gonella LA. 7)Stoppa G. 8)Lora R. 9)Pagliarini M. 10)Leone R. 11)Moretti U. |
| 95 | MUSCULAR ADVERSE DRUG REACTIONS ASSOCIATED WITH PROTON PUMP INHIBITORS: A DISPROPORTIONALITY ANALYSIS USING THE ITALIAN NATIONAL NETWORK OF PHARMACOVIGILANCE DATABASE 1)Convertino I.. 2)Capogrosso sansone A.. 3)Galiulo M.. 4)Salvadori S.. 5)Pieroni S.. 6)Knezevic T.. 7)Mantarro S.. 8)Marino A.. 9)Hauben M.. 10)Blandizzi C.. 11)Tuccori M.. |
| 96 | Interactions between vaccines against influenza and drugs for chronic diseases: the analysis of the Vaccine Adverse Event Reporting System (VAERS) and VigiBase 1)Carnovale C. 2)Raschi E. 3)Poluzzi E. 4)Leonardi L. 5)Moretti U. 6)Gentili M. 7)De ponti F. 8)Clementi E. 9)Radice S. |
| 97 | PREVENTABILITY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ADVERSE DRUG REACTION 1)Cimmaruta D. 2)Sessa M. 3)Sportiello L. 4)Mascolo A. 5)Scavone C. 6)Gallipoli S. 7)Di mauro G. 8)Rafaniello C. 9)Capuano A. |
| 98 | LONG-TERM SAFETY OF DEFERIPRONE IN CHILDREN WITH BETA-THALASSAEMIA MAJOR: COMPARATIVE DATA FROM LARGE MULTI-CENTRE PERSPECTIVE STUDIES 1)Felisi MG. 2)Botzenhardt S.. 3)Bonifazi F.. 4)Bejaoui M.. 5)Conte R.. 6)Cosmi C.. 7)Del vecchio GC. 8)El-beshlawy A.. 9)Filosa A.. 10)Kattamis A.. 11)Kreka M.. 12)Maggio A.. 13)Manfredi C.. 14)Origa R.. 15)Padula R.. 16)Putti MC. 17)Wong I.. 18)Neubert A.. 19)Bonifazi D.. 20)Ceci A.. |
| 99 | INTUSSUSCEPTION RATES BEFORE AND AFTER THE INTRODUCTION OF ROTARIX: A SINGLE-CENTRE OBSERVATIONAL STUDY. 1)Galfo F. 2)Mecchio A. 3)Puliafito A. 4)Menniti ippolito F. 5)Arrigo T. 6)Impellizzeri P. 7)Altavilla D. |
| 100 | Facilitation Of Reporting in hospital Ward (FORWARD): an active monitoring project to improve adverse drug reactions reporting 1)Giardina C. 2)Cutroneo P. 3)Mocciaro E. 4)Spina E. 5)Arcoraci V. |
| 101 | Incidence of ticagrelor-related dyspnea leading to emergency department admission: a three year population based cohort-study 1)Lombardi N. 2)Lucenteforte E. 3)Torrini M. 4)Balzi D. 5)Mugelli A. 6)Vannacci A. |
| 102 | MAPPING THE GLOBAL SAFETY PROFILE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS: ANALYSIS OF INTERNATIONAL SPONTANEOUS REPORTING SYSTEMS (FAERS, WHO-VIGIBASE, EUDRAVIGILANCE) 1)Raschi E. 2)Parisotto M. 3)Forcesi E. 4)La placa M. 5)Marchesini G. 6)Poluzzi E. 7)De ponti F. |
| 103 | SAFETY PROFILE OF BIOLOGIC DRUGS USED IN A REAL WORLD SETTING IN CAMPANIA REGION: BIO-CAM OBSERVATIONAL STUDY 1)Scavone C. 2)Bertini M. 3)Brusco S. 4)Illiano M. 5)Di mauro G. 6)Ruggiero R. 7)Rafaniello C. 8)Sportiello L. 9)Rossi F. 10)Capuano A. |